Company profile for Radius Health

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide i...
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
950 Winter Street Waltham, MA 02451
Telephone
Telephone
617-551-4000
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.accesswire.com/962075/radius-pharmaceuticals-announces-licensing-agreement-with-pharmanovia-to-register-and-commercialize-abaloparatide-in-china-and-select-asia-pacific-territories

ACCESSWIRE
02 Jan 2025

https://www.accesswire.com/951473/radius-pharmaceuticals-expands-abaloparatide-licensing-agreement-with-theramex-granting-additional-commercialization-rights-including-mexico-canada-south-africa-israel-and-russia

ACCESSWIRE
09 Dec 2024

https://www.businesswire.com/news/home/20241020898766/en

BUSINESSWIRE
21 Oct 2024

https://www.pharmaceutical-technology.com/news/fda-radius-tymlos-osteoporosis/

PHARMACEUTICAL-TECHNOLOGY
22 Dec 2022

https://pink.pharmaintelligence.informa.com/PS147138/EU-Moment-of-Truth-For-Abaloparatide--Advanced-Therapy-TabCel

PHARMAINTELLIGENCE
11 Oct 2022

https://www.globenewswire.com/news-release/2022/08/15/2498274/31149/en/Gurnet-Point-Capital-and-Patient-Square-Capital-Complete-Their-Acquisition-of-Radius-Health-Inc.html

GLOBENEWSWIRE
15 Aug 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty